Do Pharma Sa Aveta plans to set up a pharmaceutical solutes production plant in Togo

Objectives

The project involves setting up a pharmaceutical plant with an annual production capacity of 18,000,000 vials of standard serum (glucose, saline, ringer), special serum (paracetamol, ciprofloxacin), metronidazole, paracetamol and ciprofloxacin vials.

The project’s updated target is to produce standard serum (glucose, saline, ringer), special serum (paracetamol, ciprofloaxine), metronidazole, paracetamol and ciprofloxacin in 500 ml and 250 ml vials, ranging from 2,000,000 units (11% of installed capacity) in 2017 to 8,000,000 units (41% of installed capacity) in 2018, 12,000,000 units (76% of installed capacity) in 2019 and 17,000,000 units (100% of installed capacity) in 2022.

Financing
of the project

BOAD : 2300 M FCFA
Other : 5008 M FCFA

PROJECT PRESENTATION

DO PHARMA SA is planning to set up a plant to produce solid solutions. The project is designed to alleviate the shortage of saline and glucosed serum in Togo’s health establishments. It also testifies to the clear determination of the Republic of Togo to support the private sector in improving the business climate. This will help strengthen health coverage in Togo.
The pharmaceutical structure covers a 10-hectare site with a 3500m2 factory. It comprises four key departments: production, engineering, quality assurance and quality control, as well as a laboratory equipped with WHO-compliant packaging rooms.
The Do-Pharma plant will make a significant contribution to reducing dependence on pharmaceutical imports, while reinforcing the fight against medicines of dubious origin. It thus represents a significant step forward for Togo’s healthcare sector, guaranteeing a reliable local supply of essential medical products and consolidating national production capacities.

BOAD’s support resulted in the signature of a loan agreement for 2.300 billion FCFA.

COST AND FINANCING

The total cost of the project is estimated at 7,308 M FCFA, including CM FCFA financed by BOAD. The loan will help finance the cost of finishing work and production equipment and auxiliaries.

PROJECT DEVELOPMENT IMPACT

The construction and operation of the solute plant will have the following impacts:

Facilitating access to serums for the populations of Togo and UEMOA countries in general.
The availability of high-quality, low-cost sera. – Discouraging the import and sale of adulterated serums and counter-tapes.
Improved medical services with lower mortality rates.
The contribution to job creation and the improvement of staff income, thus raising the standard of living of families directly and indirectly affected by the project.
The creation of related activities such as small bars and restaurants in the vicinity of the plant.
Helping to reduce the rural exodus.
The creation of an industrial zone for medical and non-medical companies.
Increased demand for housing in the locality due to the arrival of workers and company personnel.
Improving the image of the village of Avéta and environmental localities
Increase Togo’s tax revenues.

Nos autres projets au Togo

Togo

Infrastructures and digital economies

Programme d’Urgence de Renforcement de la Résilience dans la région des Savanes (PURS) in the Republic of Togo.